NCT01149291View on ClinicalTrials.gov

A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary Hyperparathyroidism

CompletedOBSERVATIONAL
Enrollment

511

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Secondary HyperparathyroidismEnd Stage Renal Disease
Trial Locations (22)

7070

Site Reference ID/Investigator# 63763, Izmir

7130

Site Reference ID/Investigator# 68286, Antalya

33000

Site Reference ID/Investigator# 68281, Mersin

Site Reference ID/Investigator# 68282, Mersin

34180

Site Reference ID/Investigator# 85153, Istanbul

43260

Site Reference ID/Investigator# 68283, Kütahya

07059

Site Reference ID/Investigator# 37822, Antalya

Unknown

Site Reference ID/Investigator# 40677, Antalya

Site Reference ID/Investigator# 40672, Istanbul

Site Reference ID/Investigator# 40674, Istanbul

Site Reference ID/Investigator# 40678, Istanbul

Site Reference ID/Investigator# 40686, Istanbul

Site Reference ID/Investigator# 61585, Istanbul

Site Reference ID/Investigator# 63764, Istanbul

Site Reference ID/Investigator# 63765, Istanbul

Site Reference ID/Investigator# 63766, Istanbul

Site Reference ID/Investigator# 69973, Istanbul

Site Reference ID/Investigator# 48127, Izmir

Site Reference ID/Investigator# 64444, Karaman

Site Reference ID/Investigator# 40684, Kayseri

Site Reference ID/Investigator# 48132, Konya

Site Reference ID/Investigator# 69974, Mersin

All Listed Sponsors
lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01149291 - A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary Hyperparathyroidism | Biotech Hunter | Biotech Hunter